Cyclohexyl(methanidyl)azanium

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Cyclohexyl(methanidyl)azanium
• 化学式: C7H15N
• 分子量: 113.2
• InChiKey: DLJQTHWPTDNESV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  16.6
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] BETA-LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE BÊTA-LACTAMASES
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2017100537A1

  公开（公告）日：2017-06-15

  Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

  本文描述了调节β-内酰胺酶活性的化合物和组合物。在某些实施例中，所述化合物抑制β-内酰胺酶。在特定实施例中，所述化合物在治疗细菌感染方面是有用的。
• 8-Substituted isoquinoline derivative and the use thereof
  申请人：Kaneko Shunsuke

  公开号：US20100261701A1

  公开（公告）日：2010-10-14

  The present invention relates to a compound represented by the following formula (1): wherein D 1 , A 1 , D 2 , R 1 , D 3 , and R 2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

  本发明涉及一种由以下式（1）表示的化合物： 其中D1，A1，D2，R1，D3和R2分别具有与本说明书中定义的相同含义或其盐。由式（1）表示的化合物或其盐具有IKKβ抑制活性等，对于预防和/或治疗IKKβ相关疾病或症状等方面是有用的。
• PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF
  申请人：MORITA Kohei

  公开号：US20100093819A1

  公开（公告）日：2010-04-15

  A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA 2 , and thus has prostaglandin and/or leucotriene production suppressing action [X represents a halogen atom, an alkyl group which may be substituted, or the like, Y represents hydrogen atom or an alkyl group which may be substituted, and Z represents hydrogen atom or an alkyl group which may be substituted].

  由以下一般式（1）表示的化合物或其盐，具有优越的抑制对4型PLA2的活性，因此具有前列腺素和/或白三烯产生抑制作用【X代表卤素原子、可能被取代的烷基或类似物，Y代表氢原子或可能被取代的烷基，Z代表氢原子或可能被取代的烷基】。
• Imidazolyl derivatives
  申请人：Thurieau Alain Christophe

  公开号：US20070299073A1

  公开（公告）日：2007-12-27

  The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonist or antagonists of somatostatin receptors.

  本发明涉及式（I）的咪唑基衍生物，其中取代基在说明书中定义，它们可用作生长抑素受体的激动剂或拮抗剂。
• CHEMICAL COMPOUNDS
  申请人：Atkinson Francis Louis

  公开号：US20110136838A1

  公开（公告）日：2011-06-09

  The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R 1 , R 2 , R 3 , and R 4 are defined below. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及吡啶并[4,3-d]嘧啶-5(6H)-酮衍生物。具体而言，本发明涉及以下式I的化合物：其中R1、R2、R3和R4如下所定义。本发明的化合物是PDK1的抑制剂，可用于治疗由恒定活化的ACG激酶所表征的疾病，例如癌症，更具体地说是乳腺癌、结肠癌和肺癌。因此，本发明还涉及包含本发明化合物的制药组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的制药组合物来抑制PDK1活性和治疗与其相关的疾病的方法。